InnoCare Pharma
68842827.241.77% ( -0.49 )
InnoCare Pharma (688428)
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune d...
- Open
- 27.50
- High
- 27.97
- Low
- 27.15
- Prev. Close
- 27.73
- Volume
- 80.67K
- Turnover
- 221.71M
- Avg Price
- 27.48
- Bid/Ask Ratio
- --
- Amplitude
- 2.96%
- 52wk High
- 34.02
- Volume Ratio
- 0.47
- Turnover Ratio
- 2.96%
InnoCare Pharma Analyst Rating
View MoreForecast & Rating
May 1, 2026Price forecast
¥30.7212.78%
Forecast & RatingBuy
4analysts
- Strong buy75.00%
- Buy0.00%
- Hold25.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 1 day ago, 04:37 AM
InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory Filing
- PUBT · Jul 16 at 03:51 AM
InnoCare says Phase II vitiligo trial of TYK2 inhibitor soficitinib meets primary endpoint at Week 24
- Tip Ranks · Jul 15 at 06:07 AM
InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic Dermatitis
- Unusual Whales · Jul 14 at 06:25 AM
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLL
- GlobeNewswire · Jul 5 at 08:00 PM
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in China
- HK Stock Market Update · Jun 15 at 09:09 PM
InnoCare Pharma hits 52-week low, falls 2% in Hong Kong trading
